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Abstract: Antiretroviral drug resistance following pMTCT strate-
gies remains a signiﬁcant problem. With rapid advancements in next
generation sequencing technologies, there is more focus on HIV
drug-resistant variants of low frequency, or the so-called minority
variants. In South Africa, AZT monotherapy for pMTCT, similar to
World Health Organization option A, has been used since 2008. In
2010, a single dose of co-formulated TDF/FTC was included in the
strategy for prevention of resistance conferred by single-dose
nevirapine (sd NVP). The study was conducted in KwaZulu-Natal,
South Africa, among pMTCT participants who received AZT
monotherapy from 14 weeks of gestation, intrapartum AZT and sd
NVP, and postpartum sd TDF/FTC. Twenty-six specimens collected
at 6 weeks post-delivery were successfully sequenced using 454
ultra-deep sequencing. Non-nucleoside reverse transcriptase inhib-
itor (NNRTI) resistance was detected in 17 of 26 (65%) patients,
2 (7%) had Thymidine analogue mutations, and 3 (11%) had
K65R. Of the 17 patients with NNRTI resistance, 11 (65%) had
high-level NNRTI resistance, whereas 6 (35%) had intermediate
NNRTI resistance. The levels of NNRTI resistance are much
higher than would be expected, given the inclusion of antepartum
AZT and postpartum TDF/FTC. This high level of NNRTI
resistance could impact future NNRTI-containing treatment for
a large proportion of pMTCT-exposed women. The detection of
Thymidine analogue mutations highlights the need to understand
the clinical impact of these on AZT-containing antiretroviral
treatment in women exposed to AZT monotherapy.
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resistance
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INTRODUCTION
Although prevention of mother-to-child transmission
(pMTCT) strategies have recently improved with the imple-
mentation of World Health Organization (WHO) options B
and B plus,1 antiretroviral (ARV) drug resistance remains
a signiﬁcant problem in the wake of single-dose nevirapine
(sd NVP)2,3 monotherapy and dual-therapy use in resource-
limited settings. The current standard method for resistance
testing is Sanger sequencing, or so-called population sequenc-
ing, and although widely used, it is limited since the
sensitivity relies on mutations being present in 15%–20% of
the HIV quasispecies.4,5 Thus, resistance conferring mutations
present at low frequencies, or drug-resistant minority variants
(DRMVs) will be missed by Sanger sequencing. The more
sensitive technologies, commonly known as next-generation
sequencing, include the Miseq and HiScan (Illumina, San
Diego, CA), 454 GS-FLX and Junior (Roche Daignostics,
Basel, Switzerland), Pac-Bio RS II (Paciﬁc Biosciences, CA),
and Ion-Torrent PGM (Life Technologies, Thermo Fischer
Scientiﬁc, NY). Resistance testing performed using these
technologies can detect DRMVs present at low frequencies.6
These DRMVs were shown to be clinically signiﬁcant in
studies investigating non-nucleoside reverse transcriptase
inhibitor–based ART.7,8 DRMVs doubled the risk of virolog-
ical failure to ﬁrst-line NNRTI-containing antiretroviral
treatment (ART).9
Following pMTCT exposure, DRMVs that develop
may impact negatively on future ART, leading to virological
failure.10 In South Africa, zidovudine (AZT) administered
from the 14th week of pregnancy and intrapartum, together
Received for publication November 23, 2015; accepted May 23, 2016.
From the *Department of Virology, National Health Laboratory Service,
University of KwaZulu-Natal, Durban, South Africa; †IrsiCaixa AIDS
Research Institute, Badalona, Catalonia, Spain; ‡Universitat de Vic, Vic,
Catalonia, Spain; §HIV Unit, Hospital Universitari Germans Trias i Pujol,
Badalona, Catalonia, Spain; ǁUniversitat Autonoma de Barcelona, Barce-
lona, Catalonia, Spain; and ¶Department of Virology, HIV Pathogenesis
Laboratory, Nelson R Mandela Medical School, University of KwaZulu-
Natal, Durban, South Africa.
Supported by the Medical Research Council of South Africa and the National
Health Laboratory Service Research Trust (NHLSRT).
The authors have no conﬂicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s Web site (www.jaids.com).
Correspondence to: Reshmi Samuel, MD, Department of Virology, National
Health Laboratory service, Inkosi Albert Luthuli Hospital, University of
KwaZulu-Natal, Durban 4001, South Africa (e-mail: maharajr3@ukzn.ac.za).
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an
open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-
ND), where it is permissible to download and share the work provided it
is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
384 | www.jaids.com J Acquir Immune Defic Syndr  Volume 73, Number 4, December 1, 2016
with sd NVP and a stat postpartum dose of co-formulated
tenofovir (TDF) with emtricitabine (FTC) was used as the
pMTCT strategy from 2010 to 2013.11 Using Sanger
sequencing, high-level NVP resistance was detected in
34% of women in this context.12 This study therefore
further aims to determine the patterns and frequency of
DRMVs in this group of women, using ultra-deep
sequencing (UDS).
METHODS
This study was conducted at Lwazi Clinic, Addington
Hospital in Durban, South Africa. Ethical approval (BF069-09)
was obtained from the University of KwaZulu-Natal Bio-
medical Research Ethics Committee. Ninety-seven pregnant
women who did not qualify for ART as per National Guide-
lines,11 ie, CD4 count .350 cells per cubic millimeter were
recruited for the study from August 2010 until December 2011.
Data on adherence were captured at the 6-week post-delivery
visit and limited to “Yes,” “No,” or “Unsure” with regard to
receiving intrapartum AZT, sd NVP, and postpartum TDF/
FTC. Furthermore, an EDTA whole-blood specimen for HIV-1
viral load testing was collected at recruitment and at 6 weeks
post-delivery. A specimen for HIV-1 drug resistance testing
was also collected at 6 weeks post-delivery.
HIV-1 Viral Load
The viral loads were performed using an automated
Nuclisens EasyQ (bioMerieux) HIV-1 assay, which was
later replaced by the Abbot m2000sp and Abbot m2000rt
systems of extraction and real-time ampliﬁcation, respec-
tively. UDS was performed on 26 specimens which had an
HIV-1 viral load of .5000 RNA copies per milliliter, with
the exception of sample 3, where the viral load was 4604
RNA copies per milliliter.
Amplicon Design
Four sets of overlapping amplicons were designed
to cover the Reverse Transcriptase region of HIV-1
such that each signiﬁcant codon position was interrogated
by 2 separate amplicons. Primers were based on
a subtype C isolate, Genbank accession no AY772699
(http://www.ncbi.nlm.nih.gov/nuccore/AY772699). Primer
sequences are listed in Table 1.
RNA Preparation, Conventional Reverse
Transcription Polymerase Chain Reaction,
and Polymerase Chain Reaction
Two milliliter of plasma was ultracentrifuged at 14,000
rpm for 3 hours. RNA was extracted from 1 ml of plasma
using the Nuclisens EasyMag HIV-1(bioMerieux, France)
extraction system.
One-step reverse transcription (RT)-polymerase chain
reactions (PCRs) using the SuperScript III One-Step RT-PCR
System (with Platinum Taq High Fidelity; Invitrogen, Carls-
bad, CA) were performed in triplicate per specimen. The
triplicate RT-PCR products were then pooled and used for
a second round of PCR that ampliﬁed overlapping amplicons
which were also performed in triplicate per amplicon. The
PCR products were pooled, puriﬁed, and sequenced.
A volume of 3.75 ml of extracted RNA was added to the
RT-PCR reaction mix which had a ﬁnal volume of 12.5 ml.
Reagents included 2x buffer, Mg2SO4 (5 mM, ﬁnal concen-
tration of 0.6 mM), RNAse out, sterile water, SuperScript III
(Invitrogen, Carlsbad, CA), and primers 1855-F1 and 2745-
R2 (ﬁnal concentration of 0.2mM).
A reverse transcription step at 55°C for 25 minutes was
performed. Thermocycling was performed using an initial
denaturation of 94°C for 2 minutes, followed by 25 cycles of
94°C for 30 seconds, 57°C for 30 seconds, 68°C for 30
seconds and a ﬁnal extension step at 68°C for 1 minute. After
the ﬁrst round of PCR, 1 mL of the pooled PCR product was
added to the second round PCR reaction mix (ﬁnal volume of
50 mL) containing 10· buffer, dNTPs (200 mM), Platinum
Taq High Fidelity enzyme (Invitrogen), MgS04 (50 mM, ﬁnal
concentration 2 mM), and DNase free water. The reaction mix
was aliquoted equally into 4 separate tubes so that the
relevant primers for the individual amplicons were added
(F1, R1 to tube 1; F2, R2 to tube 2, etc). Conditions of cycling
were the same as for the ﬁrst round with omission of the RT
step of 55°C for 55 minutes. After pooling, 150 mL of product
was available for ultra-deep 454 sequencing. Samples were
puriﬁed using the Qiagen min Elute spin columns.
To limit random sampling error caused by the sampling of
only a few viral variants in patients with low viral loads, only
patient samples with viral loads .5000 copies per milliliter
were used, with the exception of sample 3, where the viral load
was 4604 RNA copies per milliliter. Primers were designed to
target conserved regions to limit primer induced selection bias,
where particular templates are ampliﬁed earlier than others, and
TABLE 1. Primer Sequences
Amplicon Position in AY772699 Position in HXB2 Primer Sequence
Amplicon 1 1855-F1 1855–1882 2444–2470 59-GAAATTTGTGGAAAAAAGGCTATAGG-39
2314-R1 2314–2291 2902–2880 59-ACTGAAAAATATGCATCCCCCAC-39
Amplicon 2 2368-F2 2368–2395 2957–2983 59-CAATGAAACACCAGGGATTAGATATCA-39
2745-R2 2745–2720 3334–3310 59-CCCACTAACTTCTGTATATCATTGA-39
Amplicon 3 2004-F3 2004–2028 2592–2615 59-GGAATGGATGGCCCAAAGGTTAAA-39
2439-R3 2439–2417 3027–3006 59-ATATTGCTGGTGATCCTTTCCA-39
Amplicon 4 2343-F4 2343–2368 2932–2957 5’-CTGCATTCACCATACCTAGTATAAAC-39
2686-F4 2686–2662 3275–3252 59-CTGTACTGTCCATTTGTCAGGATG-39
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these become overrepresented in the ﬁnal amplicon pool; each
sample was ampliﬁed in 3 independent PCRs, and the PCR
products were pooled before sequencing to compensate for
biased priming and random sampling error during the PCR;
multiplex identiﬁer adapters were added after the ampliﬁcation
step to avoid the selection bias induced by using fusion primers.
Ultra-Deep 454 Sequencing
UDS was performed using the Roche 454 GS-FLX at the
Technology Innovation Agency, National Genomics Platform
in Durban. Twenty-six samples were successfully sequenced.
Amplicon lengths varied in size (Amplicon 1: 459 bases,
Amplicon 2: 376 bases, Amplicon 3: 436 bases, Amplicon 4:
344 bases). Samples had to meet standard requirements for
library preparation after passing quality control. Samples were
tagged with multiplex identiﬁer adapters during library prep-
aration. After emulsion PCR, sequencing was performed
fulﬁlling all quality criteria and using a 4-lane divider on the
picotiter plate. Four standard ﬂowgram format ﬁles were
generated and used for data analysis.
Data Analysis
For statistical analysis, nonparametric methods in SPSS
version 23.0 (IBM Corp, Armonk, NY), including the Mann–
Whitney U test, were used.
For bioinformatics analysis, Amplicon Variant Ana-
lyzer software v2.7 (Roche Diagnostics, Basel, Switzerland)
was used to analyze and obtain sequence alignments against
HIV-1 subtype C reference sequence (Genbank ID:
AY772699). A short sequence length ﬁlter was applied
based on the amplicon design and the corresponding
sequence length. Short sequences (,90% of expected
sequence length) were discarded. Error-corrected consensus
sequences, as obtained from Amplicon Variant Analyzer,
were used for amino acid variant calling. Variants were
considered valid when present in both forward and reverse
directions in a balanced manner as reported elsewhere.13 To
control for sample cross-contamination, phylogenetic trees
were built for all amplicons and samples with evidence of
interfering cross-contamination were discarded. A minimum
500·/300· depth of coverage was required to call a minor
variant (#20%) and a major variant (.20%), respectively.
Depth of coverage is provided in Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A854. A 1%
conservative minimum threshold was deﬁned based on
internal sequencing controls and on published literature.13–16
To estimate whether sufﬁcient viral templates were
sampled, we used the formula pVL = NRNA(l)/(VfeERNAX-
Ec
DNA
) to calculate the minimal viral load required to
detect minor variants at 1%, where pVL is the minimum
viral load required; NRNA(l) is the number of RNA copies
that according to the Poisson distribution should be tested
to detect at least 1 minor variant with a likelihood of .
99%; V, the volume of plasma (milliliter); fe, the fraction
of the RNA eluent used for DNA synthesis; ERNAX, the
extraction yield and EcDNA, the RT efﬁciency.
17 Based on
the following V = 1 mL, ERNAX = 0.96 and EcDNA = 0.7,
using 0.5 as the fraction of the RNA eluent used for DNA
synthesis, the minimum viral load required to reliably
detect minor variants at 1% is 1488 copies per milliliter.
Viral loads of all samples that underwent 454 sequencing
were in excess of 5000 copies per milliliter, with the
exception of sample 3, where the viral load was 4604 RNA
copies per milliliter. Ensuring that an acceptable number
of templates were sampled (Table 2).
RESULTS
There was no statistical difference in the CD4 cell count
or HIV-1 viral load (at recruitment and at 6 weeks post-
delivery) between those patients who developed NNRTI
resistance and those who did not using the Mann–Whitney
U test in SPSS version 23.0 (IBM Corp).
The median overall viral load was 17,269 copies per
milliliter, with an interquartile range of 17,307 copies per
milliliter (Table 2). The median viral load among patients
where no Thymidine analogue mutations (TAMs) were
detected was 14,921 copies per milliliter (interquartile range
of 15262 copies/ml) compared with the median viral load of
93886 copies/ml in patients where TAMs were detected
(P value 0.042).
The mean duration of AZT exposure overall was 16
weeks. The median duration of AZT exposure in those who
developed TAMs was 20 weeks and 18 weeks (interquartile
range of 8 weeks) in those who did not develop TAMs
(P value 0.318).
Mutations conferring resistance to NRTIs and
NNRTIs were detected at variable frequencies (Table 2).
Of 26 patients, 20 patients (77%) had mutations conferring
resistance. NNRTI resistance was detected in 17 of 26 (65%)
patients, 2 (7%) patients had TAMs, and 3 (11%) patients
had K65R. Of the 17 patients with NNRTI resistance, 11
(65%) had high-level resistance to NVP and EFV, whereas 6
(35%) had intermediate NNRTI resistance. One patient had
both high-level NNRTI resistance and high-level resistance
to TDF and 1 patient had both low to intermediate NNRTI
resistance and K70R.
Of all mutations conferring resistance to NNRTIs, the
most common were those conferring high-level NNRTI
resistance such as K103N in 8 of 26 (30%), V106M in 8 of
26 (30%), Y188C in 6 of 26 (23%), G190A in 4 of 26
(15%), Y181C in 3 of 26 (11%), and V106A in 3 of 26
(11%) patients. K103N and V106M were the most common
mutations detected. In patients who had K103N, it was also
the predominant variant within the viral population com-
pared to the other mutations detected as minor variants
only. Mutations conferring low to intermediate NNRTI
resistance included K101E in 7 of 26 (27%), A98G 5 of 26
(19%), L100V 4 of 26 (15%), V108I in 1 of 26 (3%) and
F227L in 1 of 26 (3%) of patients. V90I which is associated
with minimal, if any, detectable reduction in NNRTI
susceptibility was found in 5 of 26 (19%) of patients.
Mutations conferring NRTI resistance included K70R in
2 of 26 (7%) patients and T69S which was detected in 1 of 26
(3%) patients. Resistance to TDF (K65R) was found in 3/26
(11%) patients. No other TAMs were detected. There was
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a 100% correlation between the mutations detected by Sanger
sequencing12 and those detected by 454 UDS in samples that
underwent both methods of sequencing. In addition, 454 UDS
was able to detect a signiﬁcant number of mutations that were
missed by Sanger sequencing as indicated in bold in Table 2.
Regarding adherence, among the patients with high-
level NNRTI resistance, 1 of 11 patients said that she was
unsure about receiving antepartum AZT and intrapartum
TDF/FTC and 1 said that she did not receive intrapartum
TDF/FTC. Among the patients where no resistance was
detected, 4 of 5 patients answered “unsure” or “no” to
receiving prophylactic ARVs.
DISCUSSION
Using UDS, higher rates of NNRTI resistance were
detected as compared to Sanger sequencing.12 More than two-
third of patients had NNRTI resistance, the majority having
high-level NNRTI resistance. The most common mutations
(30%) detected were K103N and V106M, which are associ-
ated with high-level NNRTI resistance. Most of the K103N
mutations were detected between frequencies of 17% and
59%, making it the predominant variant in the quasispecies
for those specimens (Table 2).
Resistance to sd NVP is documented to occur at an
average rate of 37.5%.18 The addition of peripartum AZT19
and postpartum TDF/FTC20 was shown to reduce the rate of
resistance conferred by sd NVP. An open-labeled random-
ized control trial in Zambia found that the addition of sd
TDF/FTC reduced NNRTI resistance by half at 6 weeks
post-delivery.21 However, in our study, despite the use of
AZT and TDF/FTC, there was no reduction in NNRTI
resistance and the rate of NNRTI resistance of 65% is
signiﬁcantly higher than in earlier pMTCT strategies where
only sd NVP was used.18 The high rate of NVP resistance
could be explained by poor adherence to the complicated
overall pMTCT strategy, exposure to NVP in successive
pregnancies,22 and the higher rates of transmitted NNRTI
drug resistance in KZN as reported by the WHO drug
resistance report of 2012.23
The clinical impact of minority NNRTI drug-resistant
variants has recently become topical following advances in
the next-generation sequencing technologies. Studies inves-
tigating this show that minority NNRTI-resistant variants are
clinically signiﬁcant and can lead to treatment failure when
these patients are initiated on NNRTI-containing
ARVs,7,8,13,16,24,25 Furthermore, even with 95% adherence,
these variants are associated with up to 3 times the risk of
virological failure.7 In addition, preexisting minority Y181C
variants were associated with a risk of virological failure in
patients initiated on ﬁrst-line efavirenz (EFV)-containing
ART24 and in EFV exposed treatment experienced patients.26
In our study, Y188C and Y181C were detected in 23% and
11%, respectively, of patients as minority variants.
The added clinical beneﬁt of using next-generation
sequencing has been demonstrated in many studies.7,26–28
Although the sensitivity is signiﬁcantly better with such
technologies, its inclusion for routine use faces many
challenges some being the large cost factor as well as the
sophisticated bioinformatics support required.
TABLE 2. Viral Loads and Mutations Detected in Each Patient (provided as the Percentage of the Variant Within the Quasispecies)
Sample
No. V/L , copies/ml K103N V106M K101E Y188C A98G V90I G190A L100V V106A Y181C K65R K70R T69S F227L V108I
1 22,673 1.6 3.1
2 150874 59 3.5 8
3 4604 8.3 2.3 2.3 17 38 2.2
4 10,182 7
5 77,163 2 4.4 2.6 1.5
6 6179 17 4.3 25 1.7
7 19,773 30.4 2.6 6.2 3.2 2.4
8 84,920 1.1
9 5067 2.4 2.5
10 102852 1.0 13 91.8
11 16,447 22 3 38 2.1 27 1.09
12 NR 1.7 1.3 2
13 9293 1.57
14 5172 13
15 8598 22 32 8 17
16 13,395 2.6
17 23,143 1.3 7.3
18 23,592 54 5 1.2 1.68 28
19 18,091 1.7
20 8903 36 13 16.6 8
21 26,778 96.9 1.4
Additional mutations detected by 454 sequencing are highlighted in bold.
NR, not recorded.
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Two (7%) patients harbored the K70R mutation while
no other TAMs were found. Although the rate of AZT
resistance is much lower than that detected by Olson et al,29 it
is possible that AZT resistant mutants may have faded by the
time of sample collection in our study, ie, 6 weeks post-
delivery and may also be reﬂective of a smaller sample size.
A study in Tanzania among pMTCT recipients where a similar
pMTCT strategy was used, found AZT resistance in 18% of
patients by Allele-speciﬁc PCR. The higher sensitivity of
Allele-speciﬁc PCR compared to deep sequencing may
explain the higher rates of TAMs.30 The clinical impact of
these minority AZT-resistant variants when patients initiate
ART requires further investigations.
K65R was detected in 11% of patients at low frequen-
cies (1%–2.6%). There are reports of higher levels of K65R
detection in HIV-1 subtype C among patients failing ﬁrst-line
TDF-based ART31,32 and in ART-naive patients.33 This high-
lights the need to explore the impact of minority TDF drug-
resistant variants in HIV-1 subtype C. The mechanism for
higher levels of K65R in subtype C seems to be template
speciﬁc, where a preferential pause in subtype C reverse
transcription at position 65 AAG-AGG is seen.34 It is therefore
important to interpret low abundance K65R mutations in
subtype C with caution. In addition, PCR-induced error is an
important consideration when interpreting very low-
abundance variants. Varghese et al35 showed that using UDS
which is PCR dependent for the sequencing of subtype C, RT
KKK template may result in spurious detection of K65R.
The limitations of this study include the lack of baseline
genotyping, limited adherence information and lack of
knowledge of previous exposure to sd NVP. Owing to the
increasing rates of transmitted NNRTI resistance,23 it is
possible that the high levels of NNRTI resistance detected
in this study is partially reﬂective of the transmitted NNRTI
resistance. However for AZT, resistance most likely devel-
oped while on short course AZT since these patients were not
exposed to ART regimens, had high HIV-1 viral loads and
prolonged AZT exposure.36,37
We have demonstrated a high level of NNRTI resis-
tance (65%), which may have serious impact on the national
ART programme in South Africa. Since this regimen was part
of the South African pMTCT prophylaxis from 2008 to
2013,11,38,39 approximately 1.5 million women may have been
exposed to this regimen, given that about 300,000 HIV-
infected women require pMTCT annually in South Africa.40
If this ﬁgure is adjusted for the average uptake of pMTCT
prophylaxis in South Africa at 58.7%,41,880,000 women
would have been exposed to this regimen. Therefore, more
than half a million women may fail ﬁrst-line NNRTI-
containing ART and require a switch to a protease inhibi-
tor–based ART regimen.
Furthermore, our extrapolation does not consider, ﬁrst,
the women exposed to sd NVP before 2008 who sub-
sequently may have developed NNRTI resistance when
initiated on ART. Second, the WHO reported in 2012 that
transmitted NNRTI resistance is increasing in Africa. The
prevalence of transmitted NNRTI resistance in KwaZulu-
Natal has increased from below 5% in 2007 to 5%–15% in
2010 with the most commonly detected mutation being the
K103NS.23 Third, the number of patients with NNRTI
mutations among those failing NNRTI-based ART is high
in rural South Africa, ie, 82% in both adults42 and children,43
with K103NS again being the most commonly detected
NNRTI mutation. Finally, the underestimation of ART
resistance using conventional sequencing and the rising
evidence of the clinical impact of minority NNRTI mutations
remains an important consideration.
These factors may consequently contribute to a higher
than expected ART failure rate among patients on ﬁrst-line
NNRTI-containing ART. Therefore, it may be prudent to
consider more rigorous monitoring for virological failure in
these women to ensure good future treatment outcomes.
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